Search | Clinical Trials Finder

Conditions: Acute Ischemic Stroke
Interventions: LT3001 drug product, Placebo, Aspirin, Clopidogrel, Apixaban, Dabigatran; Drug
Lead sponsor: Lumosa Therapeutics Co., Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Cypress, California

Conditions: Renal Insufficiency
Interventions: Midazolam oral solution, Dabigatran and pitavastatin oral solution, Atorvastatin and rosuvastatin oral solution, Rifampin; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 78 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 2
States / cities: Hialeah, Florida • Orlando, Florida

Conditions: Atrial Fibrillation
Interventions: Warfarin, Dabigatran; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 78,140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Deep Venous Thrombosis, Pulmonary Embolism
Interventions: Dabigatran: extended treatment (e.g at least 90 days), Dabigatran: extended treatment (e.g at least 180 days), Dabigatran: extended treatment (e.g at least 270 days), Apixaban: extended treatment (e.g at least 90 days), Apixaban: extended treatment (e.g at least 180 days), Apixaban: extended treatment (e.g at least 270 days), Rivaroxaban: extended treatment (e.g at least 90 days), Rivaroxaban: extended treatment (e.g at least 180 days), Rivaroxaban: extended treatment (e.g at least 270 days), Edoxaban: extended treatment (e.g at least 90 days), Edoxaban: extended treatment (e.g at least 180 days), Edoxaban: extended treatment (e.g at least 270 days), Warfarin: extended treatment (e.g at least 90 days), Warfarin: extended treatment (e.g at least 180 days), Warfarin: extended treatment (e.g at least 270 days); Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 416,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: Dabigatran etexilate (DE), Rosuvastatin, PF-07081532; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: South Miami, Florida

Conditions: Cancer, Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Blood Clot
Interventions: Rivaroxaban, Apixaban, Edoxaban, Dabigatran, Warfarin, Dalteparin, Enoxaparin, Fondaparinux; Drug
Lead sponsor: Alliance Foundation Trials, LLC.; Other
Eligibility: 18 Years and older
Enrollment: 811 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 151
States / cities: Chula Vista, California • Fremont, California • Fresno, California + 104 more

Conditions: Atrial Fibrillation
Interventions: Dabigatran (Pradaxa), Vitamin K antagonist; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 56,039 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections
Interventions: Part A, C and D: VH3739937 500 mg, Part A: VH3739937 100 mg, Part A and C: Placebo, Part B: Treatment A, Part B: Treatment B, Part B: Treatment C, Part B: Treatment D, Part B: Treatment E, Part D: Probe cocktail; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Thromboembolism
Interventions: Warfarin, Dabigatran etexilate; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 2,589 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 10
States / cities: Little Rock, Arkansas • Clearwater, Florida • Normal, Illinois + 7 more

Conditions: Healthy
Interventions: Lanabecestat, Dabigatran etexilate; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Venous Thromboembolism
Interventions: Not listed
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 7,797 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 19
States / cities: Long Beach, California • Miami, Florida • Pembroke Pines, Florida + 15 more

Conditions: Venous Thromboembolism
Interventions: dabigatran etexilate; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 1 Year to 2 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 8
States / cities: Sacramento, California • Louisville, Kentucky • Boston, Massachusetts + 5 more

Conditions: Venous Thromboembolism, Secondary Prevention
Interventions: dabigatran etexilate; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: Up to 18 Years
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 9
States / cities: Sacramento, California • Miami, Florida • Tampa, Florida + 6 more

Conditions: Healthy Participants
Interventions: Dabigatran, PF-07321332/ritonavir + Dabigatran, Ritonavir + Dabigatran; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Hollywood, Florida

Conditions: Atrial Fibrillation (AF)
Interventions: discontinue anticoagulation therapy, Anticoagulant drugs, Catheter Ablation; Behavioral · Drug · Procedure
Lead sponsor: China National Center for Cardiovascular Diseases; Government
Eligibility: 18 Years and older
Enrollment: 3,160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Atrial Fibrillation
Interventions: Not listed
Lead sponsor: Corewell Health East; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Atrial Fibrillation
Interventions: Not listed
Lead sponsor: UConn Health; Other
Eligibility: 50 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Atrial Fibrillation (AF), VTE
Interventions: PAUSE Perioperative DOAC Management, ASRA Perioperative DOAC Management; Other
Lead sponsor: McMaster University; Other
Eligibility: 18 Years and older
Enrollment: 920 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 6
States / cities: Hartford, Connecticut • Evanston, Illinois • Boston, Massachusetts + 3 more

Conditions: Stroke, Secondary Prevention
Interventions: optional ASA as comedication, placebo to ASA, placebo to optional ASA as comedication, placebo to dabigatran etexilate, ASA 100 mg, dabigatran etexilate; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 150 Years
Enrollment: 5,390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 110
States / cities: Phoenix, Arizona • Beverly Hills, California • El Cajon, California + 94 more

Conditions: Atrial Fibrillation
Interventions: Observational; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 89 Years
Enrollment: 38,499 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Drug-Interactions
Interventions: ecopipam HCl ~2mg/kg/day, Cohort 1 Probe Cocktail, Cohort 2 Probe Cocktail, Cohort 3 Probe Cocktail; Drug · Combination Product
Lead sponsor: Emalex Biosciences Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Venous Thromboembolism
Interventions: dabigatran etexilate 150 mg twice daily (BID), matching placebo twice daily (BID); Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,353 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 21
States / cities: Birmingham, Alabama • Huntsville, Alabama • Laguna Hills, California + 17 more

Conditions: Healthy
Interventions: Dabigatran etexilate mesylate, Odalasvir (ODV), Simeprevir (SMV); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Myocardial Injury After Noncardiac Surgery (MINS)
Interventions: Dabigatran, Placebo (for Dabigatran), Omeprazole, Placebo (for Omeprazole); Drug
Lead sponsor: Population Health Research Institute; Other
Eligibility: 45 Years and older
Enrollment: 1,754 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 7
States / cities: Kansas City, Kansas • Buffalo, New York • Rochester, New York + 4 more

Search by objective public record fields.

A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects

Pharmacokinetics of Midazolam, Dabigatran, Pitavastatin, Atorvastatin, and Rosuvastatin in Participants With Renal Insufficiency in the Presence and Absence of Rifampin (MK-0000-386)

Replication of the RELY Anticoagulant Trial in Healthcare Claims Data

The DARE Warfarin CER Study

A Drug-Drug Interaction Study to Estimate the Effect of PF-07081532 on the Pharmacokinetics of Dabigatran and Rosuvastatin in Overweight or Obese Adult Participants

Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer

Real-world Comparative Effectiveness of Dabigatran Versus Vitamin K Antagonist

VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect (FE), and Drug-drug Interaction (DDI)

Phase III Study Testing Efficacy & Safety of Oral Dabigatran Etexilate vs Warfarin for 6 m Treatment for Acute Symp Venous Thromboembolism (VTE)

A Drug-drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants

RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism

Pharmacokinetics, Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 2 Years of Age

Safety of Dabigatran Etexilate in Blood Clot Prevention in Children

PF-07321332/Ritonavir and Ritonavir on Dabigatran Study in Healthy Participants

Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial Fibrillation

Dabigatran Versus Warfarin Anticoagulation Before and After Catheter Ablation for the Treatment of Atrial Fibrillation

Effect of Pradaxa vs Warfarin on Bone Mass and Bone Turnover Markers

Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure

Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)

The Comparative Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-valvular Atrial Fibrillation Population With Humana Healthcare Coverage

Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates

Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term Prevention of Recurrent Symptomatic VTE

A Pharmacokinetic Interaction Study Between Odalasvir, Given as a Single Agent or in Combination With Simeprevir, and Dabigatran Etexilate Mesylate in Healthy Participants

Management of Myocardial Injury After Noncardiac Surgery Trial